OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Biological Therapy is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	104
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)	51
Statement of Retraction	49
Bispecific antibodies for the treatment of hemophilia A	47
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry	41
Belimumab for the treatment of pediatric patients with lupus nephritis	39
Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’?	36
Aflibercept biosimilars – so near, yet so far	33
Bispecific antibodies for immune cell retargeting against cancer	31
Biologic therapies for chronic obstructive pulmonary disease	31
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	30
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial	30
The potential for medical therapies to address fistulizing Crohn’s disease: a state-of-the-art review	30
The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel	29
Biological therapies for the treatment of psoriasis in pediatrics	29
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer	27
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	26
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?	25
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies	24
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease	22
Cell-based therapies for the treatment of sports injuries of the upper limb	22
Perceptions of airway gene therapy for cystic fibrosis	21
Elotuzumab in multiple myeloma	21
Biologic insights from single-cell studies of psoriasis and psoriatic arthritis	21
Corticosteroids, hyaluronic acid, platelet-rich plasma, and cell-based therapies for knee osteoarthritis - literature trends are shifting in the injectable treatments’ evidence: a systematic review an	20

Evaluation of physicochemical and biological properties of nonreconstituted MYL-1401O vials, reconstituted MYL-1401O suspension in vial, and diluted MYL-1401O suspension in infusion bags (0.9% saline)	20
Steps towards the clinical application of endometrial and menstrual fluid mesenchymal stem cells for the treatment of gynecological disorders	20
Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group	20
Literature review and expert opinion on diagnosis and current management of generalized pustular psoriasis	19
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healt	18
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	18
Analytical similarity assessment of MYL-1402O to reference Bevacizumab	18
How can clinical safety and efficacy concerns in stem cell therapy for spinal cord injury be overcome?	17
Current and Future Options of Haemophilia A Treatments	17
CAR-NK cells: a promising cellular immunotherapy in lymphoma	17
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas	16
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	16
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	16
Clinical management and innovation in fracture non-union	15
Emerging therapies for human hearing loss	14
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	14
Current and preclinical treatment options for Merkel cell carcinoma	14
Mosunetuzumab for the treatment of follicular lymphoma	14
Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives	14
Advancements in biologic therapy in eosinophilic asthma	13
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	13
Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications – an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information throu	12
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy	12
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries	12
Clinical updates in mesenchymal stromal cell therapy for osteoarthritis treatment	12
Could siRNA therapeutics change the way we treat dyslipidemia?	12
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	12
Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer	12
Antibody drug conjugates for glioblastoma: current progress towards clinical use	12
Correction	11
Non-traditional approaches for control of antibiotic resistance	11
Biological therapies in thrombocytopenia and primary antiphospholipid syndrome: where are we now?	11
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	11
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study	11
Biosimilars and access to biologic therapy in immune-mediated diseases	11
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	11
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network	11
Small molecule-regulated switches to provide functional control of CAR T cells within the patient	11
Muscle invasive bladder cancer: where is the field headed?	10
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	10
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	10
The endosomal-lysosomal system in ADC design and cancer therapy	10
The effect of platelet-rich plasma-fibrin glue dressing in combination with oral vitamin E and C for treatment of non-healing diabetic foot ulcers: a randomized, double-blind, parallel-group, clinical	10
Biologics for psoriasis: is there any unmet need left?	10
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	10
Treating psoriasis in the elderly: biologics and small molecules	10
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	10
Belimumab patient profile in Spain: evolution during the last decade and future directions	10
Signaling new therapeutic opportunities: cytokines in prostate cancer	10
Psoriasis and cancer: the role of inflammation, immunosuppression, and cancer treatment	10

Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey	10
Therapeutic monoclonal antibodies for COVID-19 management: an update	10
Long-acting delivery and therapies for neovascular age-related macular degeneration	9
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	9
Recommendations for pregnancy in Fanconi anemia	9
Developing combination therapies with biologics in triple-negative breast cancer	9
Adjuvant immunotherapy for locally advanced renal cell carcinoma	9
How should we approach salvage therapy in advanced renal cell carcinoma after first-line immunotherapy combinations?	9
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges	9
Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer	9
Considerations for the use of biological therapies in elderly patients with rheumatoid arthritis	9
Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease	9
Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease	9
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	9
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	9
Biological therapy in elderly patients with acute myeloid leukemia	9
Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease	9
What role can LAG-3-blocking antibodies play in melanoma therapy?	8
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	8
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer	8
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations	8
Cell homing strategy as a promising approach to the vitality of pulp-dentin complexes in endodontic therapy: focus on potential biomaterials	8
Onasemnogene abeparvovec for the treatment of spinal muscular atrophy	8
What’s new and what’s next for gene therapy in Pompe disease?	8
Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients?	8
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	8
The future of CAR T-cell therapy for B-cell acute lymphoblastic leukemia in pediatrics and adolescents	8
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	8
Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing	8
Harmonizing PD-L1 testing in metastatic triple negative breast cancer	8
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients	8
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study	8
IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?	8
Survivin as a biological biomarker for diagnosis and therapy	8
The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis	8
Epcoritamab in B-cell malignancies: current status and prospects	8
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	7
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	7
The role of antibody therapies in treating relapsed chronic lymphocytic leukemia: a review	7
Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to acceler	7
Correction	7
Recent advances in stem cell therapy for erectile dysfunction: a narrative review	7
Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market	7
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	7
Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy	7
Correction	7
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma	7
Oncolytic virotherapies for pediatric tumors	7
Antibody-drug conjugates in oncology: insights into Current challenges	7
Experts’ review: the emerging roles of romiplostim in immune thrombocytopenia (ITP)	7
Next-generation CD40 agonists for cancer immunotherapy	7
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	7
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma	7
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	7
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors	7